IP Library Granted Patent US 9,140,692
Granted Patent B1
US 9,140,692 · App. 12/987,034 · Granted Sep 22, 2015

Methods of identifying glycopeptides recognized by disease-associated auto-antibodies

Inventor: Edward Nudelman (Beverly, MA)
Assignee: Glycozym, Inc.
G01N33/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,140,692
App. No.
12/987,034
Granted
Sep 22, 2015
Kind
B1
Abstract

Methods for identifying glycopeptides and more particularly glycopeptide epitopes that are specifically recognized by disease-associated auto-antibodies are provided. In some aspects the auto-antibodies are cancer-associated or autoimmune disease associated. In other aspects, methods of diagnosing a patient with cancer or an autoimmune disease, or for eliciting an immune response in a mammalian host directed to the glycopeptides of the invention are provided.

Claims (3)

1. A panel of glycopeptides comprising at least a plurality of isolated glycopeptides, each isolated glycopeptide comprising a glycopeptide epitope, said epitope having been previously determined (i) to be selectively recognized by a subset of antibodies in sera from cancer patients, which subset recognizes neither (a) the corresponding naked peptides of said panel when not glycosylated; nor (b) the corresponding glycan when not bound to said peptide; and (ii) not to be recognized by antibodies in control sera, said plurality comprising at least 8 isolated glycopeptides, wherein said plurality comprises isolated glycopeptides comprising amino acid sequences of SEQ ID NOs: 86, 109, 116, 132, 134, 135, 145, and 146, wherein said glycopeptides are immobilized on said panel.

2. The panel of glycopeptides of claim 1 , wherein the plurality of isolated glycopeptides comprises SHHSDESDELVTDFPTDLPA (SEQ ID NO: 15); TPTPKEKPEAGTYSVNNGND (SEQ ID NO: 36); SESFPHPGFNMSLLENHTRQ (SEQ ID NO: 49); LAKMYYSAVEPTKDIFTGLI (SEQ ID NO: 86); TDCGGPKDHPLTCDDPRFQA (SEQ ID NO: 109); PGTSTTPSQPNSAGVQDTEM (SEQ ID NO: 116); TKTDASSTHHSTVPPLTSSN (SEQ ID NO: 132); HDVETQFNQYKTEAASRYNL (SEQ ID NO: 134); ASRYNLTISDVSVSDVPFPF (SEQ ID NO: 135); VPVTRPALGSTTPPAHDVTS (SEQ ID NO: 145); and SLASQATDTFSTVPPTPPSI (SEQ ID NO: 146).

3. The panel of glycopeptides of claim 1 , wherein the plurality comprises at least 8 and up to 30 isolated glycopeptides, wherein the plurality comprises isolated glycopeptides having amino acid sequences SEQ ID NOs: 86, 109, 116, 132, 134, 135, 145, and 146.

Assignments (3)
CHANGE OF NAME Recorded Jun 19, 2017
From: GLYCOZYM USA, INC.
To: GO THERAPEUTICS, INC.
Reel/Frame 042895/0945 →
CORRECTION BY DECLARATION REEL 026301, FRAME 0174 Recorded Jun 19, 2017
From: GLYCOZYM USA, INC.
To: GLYCOZYM USA, INC.
Reel/Frame 042896/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2011
From: NUDELMAN, EDWARD
To: GLYCOZYM, INC.
Reel/Frame 026301/0174 →
Continuity (2)
Provisional Application 61293583 · Jan 8, 2010
Provisional Application 61294477 · Jan 12, 2010